UroGen Pharma Ltd. (URGN)Healthcare | Biotechnology | Princeton, United States | NasdaqGM
43.62 USD
-1.88
(-4.132%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 43.62 |
Hot Take ↕ | Aug. 22, 2026, 5:11 a.m. EDT
The immediate setup looks like a classic biotech 'pinch' scenario where the market is pricing in a failure to sustain the recent momentum. While the company boasts impressive top-line growth (+199%) and a massive gross margin (90%), the bottom line remains deeply in the red, and the balance sheet is stretched with negative book value and burning cash. This fundamental fragility explains why the options market is screaming for downside protection, even as the stock rallies off the lows. For the short term, the heavy put volume suggests a high probability of a pullback toward the $40 support zone, making a cautious approach wise despite the accelerating price action. However, the long-term story is compelling: the company has successfully navigated a brutal multi-year decline and is now showing signs of a structural turnaround with revenue nearly doubling and a product gaining traction. The valuation is still cheap relative to its growth potential, but the path to profitability is the critical hurdle. This is a high-risk, high-reward situation where the thesis is sound, but the execution timeline remains uncertain. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.066173 |
| AutoTheta | 0.074726 |
| MSTL | 0.274971 |
| AutoETS | 0.284094 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 1.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.141 |
| Excess Kurtosis | -0.75 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.815 |
| Market Cap | 2,132,170,112 |
| Forward P/E | 15.61 |
| Beta | 1.58 |
| Profit Margins | -51.73% |
| Website | https://www.urogen.com |
As of Aug. 22, 2026, 5:11 a.m. EDT: Speculators are positioning aggressively for a downside correction in the near term, evidenced by massive volume in out-of-the-money puts (574 contracts at the $40 strike) compared to negligible put volume in the near term. Conversely, call activity shows a distinct 'pin risk' buildup at the $50 strike with significant open interest, suggesting traders are betting on a bounce or a test of resistance around current levels. The skew indicates a fear of a drop to the $30-$40 range rather than a continuation of the recent rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3297491 |
| Address1 | 400 Alexander Park Drive |
| Address2 | 4th Floor |
| All Time High | 69.568 |
| All Time Low | 3.42 |
| Ask | 50.35 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 944,470 |
| Average Daily Volume3 Month | 817,919 |
| Average Volume | 817,919 |
| Average Volume10Days | 944,470 |
| Beta | 1.575 |
| Bid | 27.77 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | -2.709 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 43.62 |
| Current Ratio | 3.802 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 45.535 |
| Day Low | 43.3898 |
| Display Name | UroGen Pharma |
| Earnings Call Timestamp End | 1,785,938,400 |
| Earnings Call Timestamp Start | 1,785,938,400 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -66,345,000 |
| Ebitda Margins | -0.35153 |
| Enterprise To Ebitda | -33.466 |
| Enterprise To Revenue | 11.764 |
| Enterprise Value | 2,220,323,328 |
| Eps Current Year | -0.24286 |
| Eps Forward | 2.79429 |
| Eps Trailing Twelve Months | -1.97 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 41.5036 |
| Fifty Day Average Change | 2.1163979 |
| Fifty Day Average Change Percent | 0.050993115 |
| Fifty Two Week Change Percent | 132.97491 |
| Fifty Two Week High | 50.81 |
| Fifty Two Week High Change | -7.1900024 |
| Fifty Two Week High Change Percent | -0.14150763 |
| Fifty Two Week Low | 15.86 |
| Fifty Two Week Low Change | 27.759998 |
| Fifty Two Week Low Change Percent | 1.7503152 |
| Fifty Two Week Range | 15.86 - 50.81 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,493,904,600,000 |
| Float Shares | 43,414,739 |
| Forward Eps | 2.79429 |
| Forward P E | 15.610405 |
| Free Cashflow | -106,975,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 300 |
| Fullday Change | -1.88 |
| Fullday Change Percent | -4.13187 |
| Fullday Price | 43.62 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.90845 |
| Gross Profits | 171,456,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03479 |
| Held Percent Institutions | 1.00097 |
| Implied Shares Outstanding | 48,880,564 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey. |
| Long Name | UroGen Pharma Ltd. |
| Market | us_market |
| Market Cap | 2,132,170,112 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_240702165 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -97,636,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,223,576,856 |
| Number Of Analyst Opinions | 8 |
| Open | 45.09 |
| Operating Cashflow | -158,916,992 |
| Operating Margins | 0.00153 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Phone | 646 768 9780 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 43.62 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 45.5 |
| Price Eps Current Year | -179.60965 |
| Price Hint | 2 |
| Price To Book | -16.101881 |
| Price To Sales Trailing12 Months | 11.297223 |
| Profit Margins | -0.51732 |
| Quick Ratio | 3.177 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.375 |
| Region | US |
| Regular Market Change | -1.88 |
| Regular Market Change Percent | -4.13187 |
| Regular Market Day High | 45.535 |
| Regular Market Day Low | 43.3898 |
| Regular Market Day Range | 43.3898 - 45.535 |
| Regular Market Open | 45.09 |
| Regular Market Previous Close | 45.5 |
| Regular Market Price | 43.62 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 580,048 |
| Return On Assets | -0.18061 |
| Revenue Growth | 1.992 |
| Revenue Per Share | 3.815 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 48,880,564 |
| Shares Percent Shares Out | 0.10479999 |
| Shares Short | 5,120,407 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,689,384 |
| Short Name | UroGen Pharma Ltd. |
| Short Percent Of Float | 0.1069 |
| Short Ratio | 5.93 |
| Source Interval | 15 |
| State | NJ |
| Symbol | URGN |
| Target High Price | 75.0 |
| Target Low Price | 48.0 |
| Target Mean Price | 60.0 |
| Target Median Price | 59.0 |
| Total Cash | 107,975,000 |
| Total Cash Per Share | 2.209 |
| Total Debt | 196,128,000 |
| Total Revenue | 188,734,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.97 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 27.669874 |
| Two Hundred Day Average Change | 15.950125 |
| Two Hundred Day Average Change Percent | 0.57644373 |
| Type Disp | Equity |
| Volume | 580,048 |
| Website | https://www.urogen.com |
| Zip | 8,540 |